

4. **Hugosson J, Carlsson S, Aus G, et al.** Mortality results from the Goteborg randomised population-based prostate-cancer screening trial. *Lancet Oncol* 2010; 11: 725–732.
5. **Schroder FH, Hugosson J, Roobol MJ, et al.** Prostate-cancer mortality at 11 years of follow-up. *N Engl J Med* 2012; 366: 981–990.
6. **Jacobsen SJ, Katusic SK, Bergstrahl EJ, et al.** Incidence of prostate cancer diagnosis in the eras before and after serum prostate-specific antigen testing. *JAMA* 1995; 274: 1445–1449.
7. **Kim EH, Andriole GL.** Prostate-specific antigen-based screening: controversy and guidelines. *BMC Med* 2015; 13: 61.
8. **Stanford JL, Stephenson RA, Coyle LM, et al.** Prostate cancer trends 1973–1995, SEER program, national cancer institute. Bethesda, MD: NIH; 1999: pub 99–4543.
9. **Wasserbauer R.** Aktivní přístup k časně detekci karcinomu prostaty – co je smysluplné a co již škodlivé. *Urol List* 2014; 12(2): 19–28.
10. **Belej K.** Screening karcinomu prostaty. *Onkologie* 2009; 3(6): 351–356.
11. **Carter HB, Albertsen PC, Barry MJ, et al.** Early detection of prostate cancer: AUA Guideline. *J Uol* 2013; 190: 419–426.
12. **Moyer VA.** U.S. Preventive services task force. Screening for prostate cancer: U.S. Preventive services task force recommendation statement. *Ann Intern Med* 2012; 157: 120–134.
13. **Andriole GL, Crawford ED, Grubb RL, et al.** Mortality results from a randomized prostate-cancer screening trial. *N Engl J Med* 2009; 360: 1797.
14. **Center MM, Jemal A, Lortet-Tieulent J, et al.** International variation in prostate cancer incidence and mortality rates. *Eur Urol* 2012; 61: 1079–1092.
15. **Lima CA, Silva AM, Kuwano AY, Rangel MR, Macedo-Lima M.** Trends in prostate cancer incidence and mortality in a mid-sized Northeastern Brazilian city. *Ver Assoc Med Bras* 2013; 59: 15–20.
16. <https://seer.cancer.gov/registries/list.html>.
17. **Ilic D, Neuberger MM, Djulbegovic M, Dahm P.** Screening for prostate cancer. *Cochrane Database Syst Rev* 2013; 1: CD004720.
18. **Shteynshlyuger A, Andriole GL.** Prostate cancer: to screen or not to screen? *Urol Clin North Am* 2010; 37: 1–9.
19. **Etzioni R, Gulati R, Falcon S, Penson DF.** Impact of PSA screening on the incidence of advanced stage prostate cancer in the United States: a surveillance modeling approach. *Med Decis Making* 2008; 28: 323–331.
20. **Crawford ED, Abrahamsson PA.** PSA-based screening for prostate cancer: how does it compare with other cancer screening tests? *Eur Urol* 2008; 54: 262–273.
21. **Welsh HG, Gorski DH, Albertsen PC.** Trends in metatatic breast and prostate cancer – lessons in cancer dynamics. *N Engl J Med* 2015; 373: 1685–1687.
22. **Lilja H, Cronin AM, Dahlin A, et al.** Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50. *Cancer* 2011; 117: 1210–1219.
23. **Vickers AJ, Ulmert D, Sjoberg DD, et al.** Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40–55 and long term risk of metastasis: case-control study. *BMJ* 2013; 346: f2023.
24. **Pena SD, Di Pietro G, Fuchshuber-Moraes M, et al.** The genomic ancestry o individuals from different geographic regions of Brazil is more uniform than expected. *PLoS One* 2011; 6: e17063.
25. **Heidenreich A, Abrahamsson PA, Artibani W, et al.** Early detection of prostate cancer: European Association of Urology recommendation. *Eur Urol* 2013; 64: 347–354.
26. **Holmstrom B, Johansson M, Bergh A, et al.** Prostate specific antigen for early detection of prostate cancer: longitudinal study. *BMJ* 2009; 339: b3537.